* Says intends to ultimately seek approval using HPV
genotyping beyond 16, 18 and 45
Source text for Eikon:
Further company coverage:
The post BRIEF-BD submits pre-market approval application to FDA for BD Onclarity HPV test appeared first on NASDAQ.